Held Might 13-16.

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR Argos Therapeutics today announced the presentation of data from the Stage 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive effect on the genetic diversity of residual HIV virus, and in addition outcomes in substantially increased time to viral rebound in HIV individuals treated with AGS-004 following antiretroviral therapy interruption. The info were discussed in an oral display at the 19th Annual Canadian Conference on HIV/AIDS Analysis , held Might 13-16, 2010 in Saskatoon, Saskatchewan. Argos plans to initiate a Phase 2b trial in the first half of 2010 cialis here . The majority of the costs of the Stage 2b trial will be funded by the National Institutes of Health, as part of a $21 million contract that Argos was awarded in 2006.

cialis france

Arena, Eisai provide update on lorcaserin NDA Arena Pharmaceuticals, Inc. and Eisai Inc. Announced today that the US Food and Drug Administration Endocrinologic and Metabolic Medications Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential dangers, when used long-term in a population of obese and overweight people to allow marketing approval. Lorcaserin, which Arena has and discovered developed, is designed for weight management, including weight maintenance and lack of weight loss, in individuals who are obese or individuals who are over weight and also have at least one weight-related co-morbid condition.

Other entries from category "nutrition":

Random entries